Brain Metastases and TP53: How Tumor Features Shape Frontline Intensification

In this segment, the panel addresses two of the most clinically relevant features that influence frontline treatment decisions in EGFR-mutant non-small cell lung cancer: brain metastases at diagnosis and TP53 co-mutation status. You will hear why the presence of brain metastases does not necessarily change the frontline regimen choice given the intracranial activity of available options, and how systemic therapy and radiation oncology are sequenced in practice. The panel also walks through the randomized data supporting intensification in TP53 co-mutated disease, what that trial tells us about the benefit of combination therapy in this subgroup, and what important questions it leaves unanswered for patients without the co-mutation.